{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:27:03Z","timestamp":1791030423767,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,10,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases inhibited by sorafenib, including Raf kinase, vascular endothelial growth factor receptors, platelet-derived growth factor receptor, and RET tyrosine kinases, we conducted an open-label phase II trial to determine the efficacy of sorafenib in patients with advanced thyroid carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Eligible patients with metastatic, iodine-refractory thyroid carcinoma received sorafenib 400 mg orally twice daily. Responses were measured radiographically every 2 to 3 months. The study end points included response rate, progression-free survival (PFS), and best response by Response Evaluation Criteria in Solid Tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were entered onto the study and treated for a minimum of 16 weeks. Seven patients (23%; 95% CI, 0.10 to 0.42) had a partial response lasting 18+ to 84 weeks. Sixteen patients (53%; 95% CI, 0.34 to 0.72) had stable disease lasting 14 to 89+ weeks. Seventeen (95%) of 19 patients for whom serial thyroglobulin levels were available showed a marked and rapid response in thyroglobulin levels with a mean decrease of 70%. The median PFS was 79 weeks. Toxicity was consistent with other sorafenib trials, although a single patient died of liver failure that was likely treatment related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sorafenib has clinically relevant antitumor activity in patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate (partial response + stable disease) of 77%, median PFS of 79 weeks, and an overall acceptable safety profile. These results represent a significant advance over chemotherapy in both response rate and PFS and support further investigation of this agent in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2008.16.3279","type":"journal-article","created":{"date-parts":[[2008,6,9]],"date-time":"2008-06-09T21:09:42Z","timestamp":1213045782000},"page":"4714-4719","source":"Crossref","is-referenced-by-count":546,"title":["Phase II Trial of Sorafenib in Advanced Thyroid Cancer"],"prefix":"10.1200","volume":"26","author":[{"given":"Vandana","family":"Gupta-Abramson","sequence":"first","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Troxel","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoma","family":"Nellore","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Puttaswamy","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryann","family":"Redlinger","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Ransone","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Mandel","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"Loevner","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia S.","family":"Brose","sequence":"additional","affiliation":[{"name":"From the Developmental Therapeutics Program of the Abramson Cancer Center and Departments of Medicine, Biostatistics and Epidemiology, Otorhinolaryngology: Head and Neck Surgery, and Radiology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.57.1.43"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12488-9"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-67-3-501"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(03)00332-6"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197401242900404"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.4.8388"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1089\/105072502320908286"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.4922"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Gupta V, Puttaswamy K, Lassoued W, et al: Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. J Clin Oncol 25:303s,2007,  (suppl; abstr 6019)","DOI":"10.1200\/jco.2007.25.18_suppl.6019"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Sherman SI, Schlumberger MJ, Droz J, et al: Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol 25:303s,2007,  (suppl; abstr 6017)","DOI":"10.1200\/jco.2007.25.18_suppl.6017"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Wells SA, Gosnell JE, Gagel RF, et al: Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. J Clin Oncol 25:303s,2007,  (suppl; abstr 6018)","DOI":"10.1200\/jco.2007.25.18_suppl.6018"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.8.625"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030305"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2004.45.5.818"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.0978"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0987"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1177\/106689690201000104"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0921"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.050711"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1534"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Ratain MJ, Flaherty KT, Stadler WM, et al, Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. J Clin Oncol 23:381s,2004,  (suppl; abstr 4501)","DOI":"10.1200\/jco.2004.22.90140.4501"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.07.960"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.01.002"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060655"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-9-200611070-00008"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1067\/msy.1999.98849"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.2418"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.16.3279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:01:10Z","timestamp":1653494470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.16.3279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,10]]},"references-count":33,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2008,10,10]]}},"alternative-id":["10.1200\/JCO.2008.16.3279"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.16.3279","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1152897.793503106","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1152897.612953","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,10]]}}}